Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
Public ClinicalTrials.gov record NCT01031680. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes, cardiovascular disease and hypertension.
Study identification
- NCT ID
- NCT01031680
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 922 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- Apr 30, 2011
- Completion
- Nov 30, 2012
- Last update posted
- Oct 28, 2013
2010 – 2012
United States locations
- U.S. sites
- 60
- U.S. states
- 25
- U.S. cities
- 60
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gulf Shores | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Burbank | California | — | — |
| Research Site | Garden Grove | California | — | — |
| Research Site | Huntington Park | California | — | — |
| Research Site | Lancaster | California | — | — |
| Research Site | Salinas | California | — | — |
| Research Site | San Marino | California | — | — |
| Research Site | San Ramon | California | — | — |
| Research Site | Tustin | California | — | — |
| Research Site | Colorado Springs | Colorado | — | — |
| Research Site | Waterbury | Connecticut | — | — |
| Research Site | Clearwater | Florida | — | — |
| Research Site | Deerfield Beach | Florida | — | — |
| Research Site | Hialeah | Florida | — | — |
| Research Site | Hollywood | Florida | — | — |
| Research Site | Jacksonville | Florida | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Port Charlotte | Florida | — | — |
| Research Site | Port Orange | Florida | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Winter Park | Florida | — | — |
| Research Site | Columbus | Georgia | — | — |
| Research Site | Decatur | Georgia | — | — |
| Research Site | Stone Mountain | Georgia | — | — |
| Research Site | Honolulu | Hawaii | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Wichita | Kansas | — | — |
| Research Site | Baton Rouge | Louisiana | — | — |
| Research Site | Lake Charles | Louisiana | — | — |
| Research Site | West Monroe | Louisiana | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Kansas City | Missouri | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Las Vegas | Nevada | — | — |
| Research Site | Brick | New Jersey | — | — |
| Research Site | Oradell | New Jersey | — | — |
| Research Site | New Hyde Park | New York | — | — |
| Research Site | The Bronx | New York | — | — |
| Research Site | Cincinnati | Ohio | — | — |
| Research Site | Dayton | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Phoenixville | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Reading | Pennsylvania | — | — |
| Research Site | Charleston | South Carolina | — | — |
| Research Site | Kingsport | Tennessee | — | — |
| Research Site | Carrollton | Texas | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Fort Worth | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | North Richland Hills | Texas | — | — |
| Research Site | Plano | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Tomball | Texas | — | — |
| Research Site | Ogden | Utah | — | — |
| Research Site | Danville | Virginia | — | — |
| Research Site | Spokane | Washington | — | — |
| Research Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01031680, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01031680 live on ClinicalTrials.gov.